22Nd Cntry receives Investment Bank Analyst Rating Update
22nd Century Group (NASDAQ:XXII) reported Q2 EPS of ($0.06), in-line with the analyst estimate of ($0.06). Revenue for the quarter came in at $14.5 million versus the consensus...
By Vlad Schepkov Shares of 22nd Century Group (NASDAQ:XXII) are among the most active movers in Wednesday's midday session, gaining about 25% in heavy trading, following the...
Teenagers have been using flavored e-cigarettes as a trendy alternative to the paper rolls. But, President Trump and his administration, on Sep 11, threatened to ban flavored...
22nd Century Group, Inc. is an agricultural biotechnology and intellectual property company. The Company is focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science. In tobacco, hemp/cannabis, and hop plants, it uses various plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding to deliver solutions for the life science and consumer products industries by creating new plants with optimized alkaloid and flavonoid profiles as well as improved yields and valuable agronomic traits. It has developed very low nicotine content (VLNC) tobacco and cigarettes, which contain 95% less nicotine than conventional tobacco and cigarettes. Its reduced nicotine cigarettes include VLN King and VLN Menthol King. In hemp, the Company is developing hemp varieties with increased levels of certain cannabinoids and other desirable agronomic traits.